Zalicus Inc (ZLCS.OQ)
ZLCS.OQ on NASDAQ Stock Exchange Capital Market
0.49USD
1 Aug 2013
0.49USD
1 Aug 2013
Price Change (% chg)
$0.01 (+2.13%)
$0.01 (+2.13%)
Prev Close
$0.48
$0.48
Open
$0.48
$0.48
Day's High
$0.49
$0.49
Day's Low
$0.48
$0.48
Volume
62,287
62,287
Avg. Vol
112,574
112,574
52-wk High
$1.54
$1.54
52-wk Low
$0.43
$0.43
About
Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating... (more)
Overall
| Beta: | 2.35 |
| Market Cap (Mil.): | $61.41 |
| Shares Outstanding (Mil.): | 127.26 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ZLCS.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.32 | -- | -- |
| ROI: | -80.96 | -2.58 | 18.76 |
| ROE: | -112.14 | -2.66 | 19.59 |
Competitors
| Price | Change | |
|---|---|---|
| Covidien plc (COV.N) | $63.02 | +1.39 |
| Actavis Inc (ACT.N) | $135.56 | +1.29 |
| Johnson & Johnson (JNJ.N) | $94.11 | +0.61 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.45 | +0.28 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| Pfizer Inc. (PFE.N) | $29.33 | +0.10 |
| Abbott Laboratories (ABT.N) | $36.95 | +0.32 |
| Bayer AG (BAYGn.DE) | €89.43 | +2.08 |
| Bayer AG (BAYE.F) | -- | -- |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

